OOIR: Observatory of International Research

Papers

(The H4-Index of Cardiovascular Diabetology is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin	263
Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome	157
Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations	153
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin	147
Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies	143
Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity	131
Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference	127
Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19	110
Glycemic variability: adverse clinical outcomes and how to improve it?	108
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries	104
SGLT2i: beyond the glucose-lowering effect	102
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)	102
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study	100
Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome	99
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs	97
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial	95
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort	95
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease	91
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis	90
The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study	89
Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study	86
Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort	86
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury	86
Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline	84
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials	83

Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China	81
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)	80
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction	77
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes	77
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry	76
Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study	76
Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study	74
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management	73
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analy	72
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study	71
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis	71
Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up	71
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications	67
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19	67
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte	66
Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study	66
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs	65
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA	65
Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes	62
Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach	62
Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population	61
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system	61
Direct cardiac effects of SGLT2 inhibitors	60
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs	60
Empagliflozin prevents doxorubicin-induced myocardial dysfunction	60
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes	58
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins	58
A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study	56
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study	56
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy	54